• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    10/1/25 7:01:23 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email
    avtx-20250929
    0001534120false00015341202025-09-292025-09-29


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549  

    FORM 8-K
     

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 29, 2025

    AVALO THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)  
    Delaware
    (State or other jurisdiction of incorporation)
    001-3759045-0705648
    (Commission File Number)(IRS Employer Identification No.)
    1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087
    (Address of principal executive offices) (Zip Code)
    Registrant’s Telephone Number, Including Area Code: (410) 522-8707

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 Par ValueAVTXNasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On October 1, 2025, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025.

    Taylor Boyd - Chief Business Officer

    Mr. Boyd, 37 years old, has nearly 15 years of experience across biotech business development, corporate finance, and investment banking. Most recently, he served as Executive Vice President & Chief Business Officer at Abzena Limited (“Abzena”), where he led strategic mergers and acquisitions, licensing, and portfolio expansion initiatives. Prior to Abzena, he was Vice President and Head of Business Development at Longboard Pharmaceuticals, Inc. (“Longboard”), where he led activities that ultimately culminated with its $2.6 billion acquisition by Lundbeck. Prior to Longboard, he held leadership roles at Oxford Biomedica, and investment banking roles at Raymond James, SVB Leerink, Cantor Fitzgerald, and RBC Capital Markets where he executed more than $40 billion in mergers and acquisitions and debt and equity capital markets transactions. Mr. Boyd earned his B.S. in Accountancy with a concentration in Managerial Accounting from North Carolina State University and his M.S. in Accountancy with a concentration in Transaction Advisory Services from Wake Forest University’s Babcock Graduate School of Management.

    In connection with Mr. Boyd’s appointment as Chief Business Officer, the Company and Mr. Boyd entered into an employment agreement dated September 29, 2025 (the “Boyd Employment Agreement”) and effective October 1, 2025. Pursuant to the Boyd Employment Agreement, the Company has agreed to provide Mr. Boyd with (i) a base salary of $465,000 and (ii) a discretionary annual bonus with a target amount of up to 40% of his base salary, which may be paid in cash or, if mutually agreed by the Company and Mr. Boyd, immediately vested equity. As an inducement to entering into the Boyd Employment Agreement, the Company agreed to grant Mr. Boyd a stock option to purchase 275,000 shares of the Company’s common stock, vesting over four years, with the first 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to Mr. Boyd’s continued employment with the Company on each applicable vesting date (the “Inducement Grant”). The Inducement Grant will be granted on October 1, 2025 (the “Grant Date”), with an exercise price equal to the closing price of the Company’s common stock on The Nasdaq Capital Market on the Grant Date.

    In the event Mr. Boyd’s employment is terminated by the Company without Cause or by Mr. Boyd for Good Reason (as each term is defined in the Boyd Employment Agreement), Mr. Boyd will be entitled to: (i) his accrued salary and benefits through the date of termination, (ii) if not yet paid, his earned but unpaid bonus for the prior year, based on the achievement of Company goals as determined by the Compensation Committee, (iii) nine months of his then-current monthly base salary (extended to 12 months if Mr. Boyd’s termination occurs within six months following a Change in Control, as defined in the Boyd Employment Agreement), (iv) his prorated bonus for the fiscal year in which such termination occurs, based on the achievement of Company goals as determined by the Compensation Committee (increased to 100% of his bonus if Mr. Boyd’s termination occurs withing six months following a Change in Control), (v) full vesting of his outstanding options and six months in which to exercise the options, and (vi) up to 12 months of COBRA premium payments. All of Mr. Boyd’s severance benefits are subject to his execution of a release of claims and his continued compliance with certain restrictive covenants, including perpetual confidentiality and non-disparagement covenants, invention assignment provisions, and 12-month post-employment non-competition and non-solicitation covenants.

    Mr. Boyd does not have any familial relationships with any executive officer or director of the Company and there is no arrangement or understanding between Mr. Boyd and any other person pursuant to which he was selected to serve as Chief Business Officer. There have been no transactions in which the Company has participated and in which Mr. Boyd had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

    The foregoing summary of the material terms of the Boyd Employment Agreement is qualified in its entirety by reference to the complete text of the agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
    1


    Item 8.01    Other Events.

    On October 1, 2025, the Company issued a press release announcing the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 9.01    Financial Statements and Exhibits.

    (d)    Exhibits:

    Exhibit No. Description
    10.1+
    Employment Agreement, dated September 29, 2025, by and between Avalo Therapeutics, Inc. and Taylor Boyd.
    99.1
    Press Release, dated October 1, 2025.
    104The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL.
    + Management contract or compensation plan or arrangement.


    2


    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    AVALO THERAPEUTICS, INC.
    Date: October 1, 2025By:/s/ Christopher Sullivan
    Christopher Sullivan
    Chief Financial Officer



    3
    Get the next $AVTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTX

    DatePrice TargetRatingAnalyst
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    9/5/2025Buy
    TD Cowen
    8/15/2025Overweight
    Cantor Fitzgerald
    6/2/2025$15.00Buy
    H.C. Wainwright
    3/25/2025$36.00Buy
    Stifel
    3/25/2025$23.00Buy
    Jefferies
    2/28/2025$48.00Overweight
    Piper Sandler
    2/21/2025$18.00Outperform
    Wedbush
    More analyst ratings

    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics to Participate in Upcoming Investor Conferences

    WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and Inflammation ForumFireside ChatSeptember 15, 2025, at 11:00 am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section

    8/27/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Avalo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

    9/17/25 11:38:46 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Avalo Therapeutics

    TD Cowen initiated coverage of Avalo Therapeutics with a rating of Buy

    9/5/25 7:58:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Avalo Therapeutics

    Cantor Fitzgerald initiated coverage of Avalo Therapeutics with a rating of Overweight

    8/15/25 8:18:27 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    11/14/24 5:21:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    SEC Filings

    View All

    Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

    10/1/25 7:01:23 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

    9/22/25 7:01:39 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    8/14/25 6:00:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Truex Samantha

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    6/18/25 4:44:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chan Mitchell

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    6/18/25 4:39:54 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Goldman Jonathan

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    6/18/25 4:35:44 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

    6/18/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

    SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 12:05:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

    SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/7/24 5:00:07 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care